Comparative Pharmacology
Head-to-head clinical analysis: CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER versus KEFLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER versus KEFLET.
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER vs KEFLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. It is resistant to many beta-lactamases.
Keflet (warfarin) inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of clotting factors II, VII, IX, and X in the liver.
1-2 g IV every 6-8 hours. Maximum 12 g/day.
500 mg orally every 12 hours for 10-14 days; for uncomplicated UTI: 250 mg orally every 12 hours for 7 days.
None Documented
None Documented
Terminal elimination half-life: 0.7-1.1 hours (normal renal function); prolonged to 5-13 hours in severe renal impairment (CrCl <10 mL/min)
0.5-1 hour; prolonged in renal impairment (up to 20-30 hours in ESRD).
Renal: 85-90% unchanged via glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic